Combination therapy for programmed death-1 (PD-1) blockade using mitochondrial activators, especially peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), may be the next focus of cancer research, says an expert.
The introduction of early specialist palliative care for patients recently diagnosed with malignant pleural mesothelioma (MPM) has no impact on the quality of life (QOL) scores, reveals a research presented by Professor Fraser Brims, of Curtin University Australia, at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
PD-L1 biomarker testing to guide the use of pembrolizumab in first-line treatment of metastatic non-small-cell lung cancer (NSCLC) is cost-effective from a Hong Kong healthcare payer perspective, according to results of a study presented at the 18th World Conference on Lung Cancer (WCLC) held recently in Yokohama, Japan.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.